会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Cephalosporin compounds
    • CEPHALOSPORIN化合物
    • US5114933A
    • 1992-05-19
    • US124213
    • 1987-11-23
    • Alain M. BertrandieThomas G. C. BirdFrederic H. Jung
    • Alain M. BertrandieThomas G. C. BirdFrederic H. Jung
    • A61K31/545A61K31/546A61P31/04C07D463/00C07D501/22C07D501/24C07D501/34C07D501/46C07D501/57C07D507/04C07D507/06C07D507/08
    • A61K31/545
    • Cephalosporin compounds having a 3-position substituent of the formula (I) are described:--CH.sub.2 --Y--Q (I)wherein Y is a bond or a linking group --NR.sup.4 --Y'--, --O--Y'--, 13 S--Y'-- wherein R.sup.4 is hydrogen, various optionally substituted alkyl groups, alkenyl, alkanoyl or alkanesulphonyl, and Y' is a bond or various optionally substituted alkylene groups; and Q is a benzene ring (optionally fused to a further benzene ring so forming a naphthyl group or optionally fused to a 5 or 6 membered heterocyclic aromatic group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur), said benzene ring being substituted by groups R.sup.1 and R.sup.2 which are ortho with respect to one another, wherein R.sup.1 is hydroxy or an in vivo hydrolyzable ester thereof and R.sup.2 is hydroxy, and in vivo hydrolyzable ester thereof, carboxy, sulpho, hydroxymethyl, methanesulphonamido or ureido; or Q is a group of the formula (II) or (III): ##STR1## wherein M is oxygen or a group NR.sup.3 wherein R.sup.3 is hydrogen or C.sub.1-4 alkyl; ring Q being further optionally substituted.The use of such compounds as antibacterial agents is described as are processes for their preparation and intermediates therefor.
    • 描述了具有式(I)的3-位取代基的头孢菌素化合物:其中Y是一个键的-CH 2 -YQ(I)或连接基-NR4-Y',-Y-Y',13 S- Y'-其中R 4是氢,各种任选取代的烷基,烯基,烷酰基或烷磺酰基,Y'是一个键或各种任选取代的亚烷基; 并且Q是苯环(任选地与另外的苯环稠合形成萘基或任选地与含有1,2或3个选自氮,氧和硫的杂原子的5或6元杂环芳族基团稠合),所述苯环 其中R 1为羟基或其体内可水解的酯,R2为羟基,其体内可水解的酯,羧基,磺基,羟基甲基,甲磺酰氨基或脲基的基团R 1和R 2取代; 或Q是式(II)或(III)的基团:其中M是氧或NR 3,其中R 3是氢或C 1-4烷基; 环Q进一步任选被取代。 这些化合物作为抗菌剂的使用被描述为它们的制备方法及其中间体。
    • 2. 发明授权
    • Cephalosporin derivatives
    • 头孢菌素衍生物
    • US5017569A
    • 1991-05-21
    • US117619
    • 1987-11-06
    • Alain M. BertrandieThomas G. C. BirdFrederic H. JungJean-Jacques M. Lohmann
    • Alain M. BertrandieThomas G. C. BirdFrederic H. JungJean-Jacques M. Lohmann
    • C07D501/38A61K20060101A61K9/00A61K31/545A61K31/546A61P31/04C07D20060101C07D471/00C07D501/00C07D501/18C07D501/34C07D501/36C07D501/46
    • C07D501/36C07D501/34C07D501/46
    • Cephalosporin compounds having a 3-position substituent of the formula (I) are described:--CH.sub.2 --Y--Q (I)wherein Y is a linking group --NR.sup.4 CO--Y'--, --NR.sup.4 SO.sub.2 --Y'--, --OCO--Y;-- or --SCO--Y'-- wherein R.sup.4 is hydrogen, various optionally substituted alkyl groups or alkenyl and Y' is a bond or various optionally substituted alkylene or alkenylene groups; and Q is a benzene ring (optionally fused to a further benzene ring so forming a naphthyl group or optionally fused to a 5 or 6 membered heterocyclic aromatic group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur), said benzene ring (or in the case of naphthyl either benzene ring) being substituted by groups R.sup.1 and R.sup.2 which are ortho with respect to one another, wherein R.sup.1 is hydroxy or an in vivo hydrolyzable ester thereof and R.sup.2 is hydroxy, an in vivo hydrolyzable ester thereof, carboxy, sulpho, hydroxymethyl, methanesulphonamido or ureido; or Q is a group of the formula (II) or (III): ##STR1## wherein M is oxygen or a group NR.sup.3 wherein R.sup.3 is hydrogen or C.sub.1-4 alkyl; ring Q being further optionally substituted.The use of such compounds as antibacterial agents is described as are processes for their preparation and intermediates therefor.
    • 描述了具有式(I)的3-位取代基的头孢菌素化合物:其中Y是连接基-NR4CO-Y'-,-NR4SO2-Y'-,-OCO-Y的-CH2-YQ(Ⅰ) 或-SCO-Y'-,其中R 4是氢,各种任选取代的烷基或烯基,Y'是一个键或各种任选取代的亚烷基或亚烯基; 并且Q是苯环(任选地与另外的苯环稠合形成萘基或任选地与含有1,2或3个选自氮,氧和硫的杂原子的5或6元杂环芳族基团稠合),所述苯环 (或萘基为苯环的情况)被相互相邻的基团R1和R2取代,其中R1是羟基或其体内可水解的酯,R2是羟基,其体内可水解的酯, 羧基,磺基,羟甲基,甲磺酰氨基或脲基; 或Q是式(II)或(III)的基团:其中M是氧或NR 3,其中R 3是氢或C 1-4烷基; 环Q进一步任选被取代。 这些化合物作为抗菌剂的使用被描述为它们的制备方法及其中间体。
    • 3. 发明授权
    • Oxime derivatives
    • 肟衍生物
    • US5482966A
    • 1996-01-09
    • US240464
    • 1994-06-13
    • Thomas G. C. BirdPatrick Ple
    • Thomas G. C. BirdPatrick Ple
    • A61K31/425A61K31/505A61P29/00A61P37/08A61P43/00C07D239/42C07D307/20C07D309/08C07D309/10C07D317/22C07D405/04C07D409/02C07D409/04C07D409/12C07D417/04C07D417/12A61K31/35A61K31/34
    • C07D405/04C07D307/20C07D309/10C07D317/22C07D409/04C07D417/04
    • The invention concerns oxime derivatives of the formula I ##STR1## wherein R.sup.4 includes hydrogen, carboxy, carbamoyl, amino, cyano, trifluoromethyl, (1-4C)alkylamino, di-(1-4C)alkylamino and (1-4C)alkyl;R.sup.5 includes hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, (2-5C)alkanoyl, halogeno-(2-4C)alkyl and hydroxy-(2-4C)alkyl;Ar.sup.1 is phenylene or a heteroaryl diradical;A.sup.1 is a direct link to X.sup.1, or A.sup.1 is (1-4C)alkylene;X.sup.1 is oxy, thio, sulphinyl or sulphonyl;Ar.sup.2 is phenylene or a heteroaryl diradical;R.sup.1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; andR.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which together with the carbon atom to which A.sup.2 and A.sup.3 are attached define a ring having 5 or 6 ring atoms, wherein each of A.sup.2 and A.sup.3 is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino;or a pharmaceutically-acceptable salt thereof;processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.
    • 本发明涉及式I的肟衍生物,其中R 4包括氢,羧基,氨基甲酰基,氨基,氰基,三氟甲基,(1-4C)烷基氨基,二(1-4C)烷基氨基和(1-4C)烷基 ; R5包括氢,(1-4C)烷基,(3-4C)烯基,(3-4C)炔基,(2-5C)烷酰基,卤代 - (2-4C)烷基和羟基 - (2-4C)烷基; Ar1是亚苯基或杂芳基双基; A1是直接连接到X1,或A1是(1-4C)亚烷基; X1是氧基,硫基,亚磺酰基或磺酰基; Ar 2是亚苯基或杂芳基双基; R1是(1-4C)烷基,(3-4C)烯基或(3-4C)炔基; 并且R2和R3一起形成式-A2-X2-A3-的基团,其与A2和A3所连接的碳原子一起形成具有5或6个环原子的环,其中A2和A3各自为(1 -3C)亚烷基,X 2为氧基,硫基,亚磺酰基,磺酰基或亚氨基; 或其药学上可接受的盐; 制造过程; 含有它们的药物组合物及其作为5-脂肪氧合酶抑制剂的用途。
    • 5. 发明授权
    • Diaryl ether cyclic ethers
    • 二芳基醚环醚
    • US5137913A
    • 1992-08-11
    • US806775
    • 1991-12-12
    • Thomas G. C. BirdPhilip N. Edwards
    • Thomas G. C. BirdPhilip N. Edwards
    • A61K31/075A61K31/335A61K31/357A61K31/44A61P29/00A61P37/08A61P43/00C07D20060101C07D317/22
    • C07D317/22
    • The invention concerns a diaryl ether cyclic ether of the formula I, or a pharmaceutically-acceptable salt thereof, ##STR1## wherein Ar.sup.1 is optionally substituted phenyl or naphthyl;X.sup.1 is oxy, thio, sulphinyl or sulphonyl;Ar.sup.2 is optionally substituted phenylene, or a 6-membered heterocyclene moiety containing up to three nitrogen atoms;R.sup.1 and R.sup.2 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- wherein each of A.sup.2 and A.sup.3 is (1-4C) alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino; andR.sup.3 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and substituted (1-4C)alkyl.The invention also concerns processes for the manufacture of a diaryl ether cyclic ether of the formula I, or a pharmaceutically-acceptable salt thereof, and pharmaceutical compositions containing said cyclic ether. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.
    • 本发明涉及式I的二芳基醚环醚或其药学上可接受的盐,其中Ar 1是任选取代的苯基或萘基; X1是氧基,硫基,亚磺酰基或磺酰基; Ar 2是任选取代的亚苯基或含有至多三个氮原子的6-元杂环烯部分; R1和R2一起形成式-A2-X2-A3-的基团,其中A2和A3各自为(1-4C)亚烷基,X2为氧基,硫基,亚磺酰基,磺酰基或亚氨基; (1-6C)烷基,(2-6C)烯基,(2-6C)炔基和取代的(1-4C)烷基。 本发明还涉及制备式I的二芳基醚环醚或其药学上可接受的盐的方法和含有所述环醚的药物组合物。 本发明的化合物是5-脂氧合酶的抑制剂。
    • 9. 发明授权
    • Diaryl ether cycloalkanes
    • 二芳基醚环烷烃
    • US5214070A
    • 1993-05-25
    • US750735
    • 1991-08-21
    • Thomas G. C. BirdPhilip N. Edwards
    • Thomas G. C. BirdPhilip N. Edwards
    • C07C323/18
    • C07C323/18Y10S514/886
    • The invention concerns a diaryl ether cycloalkane of the formula I, or a pharmaceutically-acceptable salt thereof, ##STR1## wherein Ar.sup.1 is optionally substituted phenyl or naphthyl; X.sup.1 is oxy, thio, sulphinyl or sulphonyl;Ar.sup.2 is optionally substituted phenylene, or a 6-membered heterocyclene moiety containing up to three nitrogen atoms;R.sup.1 is (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; andR.sup.2 and R.sup.3 together form a (3-6C)alkylene group which defines an optionally substituted ring having 4 to 7 ring atoms.The invention also concerns processes for the manufacture of a diaryl ether cycloalkane of the formula I, or a pharmaceutically-acceptable salt thereof, and pharmaceutical compositions containing said cycloalkane. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.
    • 本发明涉及式I的二芳基醚环烷烃或其药学上可接受的盐,其中Ar 1是任选取代的苯基或萘基; X1是氧基,硫基,亚磺酰基或磺酰基; Ar 2是任选取代的亚苯基或含有至多三个氮原子的6-元杂环烯部分; R1为(1-6C)烷基,(3-6C)烯基,(3-6C)炔基,氰基 - (1-4C)烷基或(2-4C)烷酰基或任选取代的苯甲酰基; 并且R 2和R 3一起形成(3-6C)亚烷基,该亚烷基定义任选具有4至7个环原子的环。 本发明还涉及制备式I的二芳基醚环烷烃或其药学上可接受的盐以及含有所述环烷烃的药物组合物的方法。 本发明的化合物是5-脂氧合酶的抑制剂。
    • 10. 发明授权
    • Thiazole derivatives
    • 噻唑衍生物
    • US5478843A
    • 1995-12-26
    • US277890
    • 1994-07-20
    • Thomas G. C. Bird
    • Thomas G. C. Bird
    • C07D417/14C07D215/227A61K31/47C07D215/36C07D417/12
    • C07D417/14
    • The invention concerns a thiazole derivative of the formula I ##STR1## wherein Q is 2-oxo-1,2,3,4-tetrahydroquinolin-6-yl or 2-oxo-1,2-dihydroquinolin-6-yl which bears on the nitrogen atom at the 1-position a (1-4C)alkyl substituent;X.sup.1 is thio, sulphinyl or sulphonyl;Ar is thiazolediyl;R.sup.1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; andR.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which together with the carbon atom to which A.sup.2 and A.sup.3 are attached define a ring having 5 or 6 ring atoms, wherein A.sup.2 and A.sup.3, which may be the same or different, each is (1-3C)alkylene and X.sup.2 is oxy, and which ring may bear one or two (1-4C)alkyl substituents;or a pharmaceutically-acceptable salt thereof;processes for their preparation; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.
    • 本发明涉及式I的噻唑衍生物,其中Q是2-氧代-1,2,3,4-四氢喹啉-6-基或2-氧代-1,2-二氢喹啉-6-基,其中带有 在1-位上的氮原子a(1-4C)烷基取代基; X1是硫代,亚磺酰基或磺酰基; Ar是噻唑二基; R1是(1-4C)烷基,(3-4C)烯基或(3-4C)炔基; 并且R2和R3一起形成式-A2-X2-A3-的基团,其与A2和A3所连接的碳原子一起定义为具有5或6个环原子的环,其中A2和A3可以是 相同或不同,各自为(1-3C)亚烷基,X2为氧基,并且该环可以带有一个或两个(1-4C)烷基取代基; 或其药学上可接受的盐; 其准备过程; 含有它们的药物组合物及其作为5-脂肪氧合酶抑制剂的用途。